Showing results (811-820 of 830) with videos related to
Sort By:
Pageof 83
Hipertension Y Riesgo Vascular|September 24, 2022
[2022 Practice guidelines for the management of arterial hypertension of the Spanish Society of Hypertension]M Gorostidi, T Gijón-Conde, A de la Sierra, et al.The Journal of Allergy and Clinical Immunology. in Practice|May 25, 2024
Clinical-Hematological Changes and Predictors of Severity in Acute Food Protein-Induced Enterocolitis Syndrome Reactions at Oral Food Challenge: A Multicenter Observational StudyL Argiz, M Valsami-Fokianos, S Arasi, et al.The Journal of Bone and Joint Surgery. American Volume|June 21, 2022
An Enhanced Understanding of Culture-Negative Periprosthetic Joint Infection with Next-Generation Sequencing: A Multicenter StudyKaran Goswami, Samuel Clarkson, Caleb D Phillips, et al.Semergen|February 19, 2022
Evaluation of prophylaxis in primary prevention with acetylsalicylic acid in people with diabetes: A scoping reviewA Ruiz-García, V Pallarés-Carratalá, A Serrano-Cumplido, et al.The Journal of Bone and Joint Surgery. American Volume|May 16, 2023
The Microbiome of Osteoarthritic Hip and Knee Joints: A Prospective Multicenter InvestigationKaran Goswami, Samuel Clarkson, Craig Tipton, et al.Oncoimmunology|May 4, 2016
Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanomaZachary A Cooper, Alexandre Reuben, Christine N Spencer, et al.JAMA Network Open|February 20, 2026
CYP2D6-Guided Opioid Management and Postoperative Pain Control: A Randomized Clinical TrialLarisa H Cavallari, Rachel A Myers, Hrishikesh Chakraborty, et al.The Lancet. Oncology|January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trialRodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.Clinical and Translational Science|July 28, 2022
Implementing a pragmatic clinical trial to tailor opioids for acute pain on behalf of the IGNITE ADOPT PGx investigatorsLarisa H Cavallari, Emily Cicali, Kristin Wiisanen, et al.Pageof 83